Megestrol acetate

Generic Name: Megestrol acetate

Brand Names: Megace

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₂O_₄

CAS Number: 595-33-5

Unique Ingredient Identifier: TJ2M0FR8ES

Background: 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.

Indication: For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.

Associated Conditions: Anorexia, Cachexia, Inoperable Carcinoma of Breast, Inoperable Endometrial Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Endometrial Carcinoma, Significant, Unexplained Weight Loss, Metastatic Endometrial carcinoma

Associated Therapies: Palliative Treatment

Clinical Trials

Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

Phase 2

Terminated

Conditions: High Grade Squamous Intraepithelial Neoplasia
Stage 0 Uterine Corpus Cancer

Interventions: Procedure: Biopsy
Other: Laboratory Biomarker Analysis
Drug: Megestrol Acetate
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2007-07-19

Last Posted Date: 2020-11-03

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 9

Registration Number: NCT00503581

Locations: 🇺🇸
Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States
🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States

and more 47 locations

Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients

Phase 2

Terminated

Conditions: Dementia

Interventions: Drug: Placebo
Drug: Megestrol acetate

First Posted Date: 2007-07-18

Last Posted Date: 2011-06-08

Lead Sponsor: Rottapharm Spain

Target Recruit Count: 39

Registration Number: NCT00503516

Locations: 🇪🇸
Hospital Socio Sanitario del Hospitalet, El Hospitalet, Barcelona, Spain

Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

Phase 2

Completed

Conditions: Atypical Endometrial Hyperplasia
Endometrial Carcinoma

Interventions: Drug: Megestrol Acetate

First Posted Date: 2007-06-07

Last Posted Date: 2018-04-04

Lead Sponsor: NYU Langone Health

Target Recruit Count: 31

Registration Number: NCT00483327

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States

High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma

Phase 1

Conditions: Endometrial Cancer
Breast Cancer
Malignant Mesothelioma

First Posted Date: 2004-07-19

Last Posted Date: 2013-11-06

Lead Sponsor: St. Vincent Medical Center - Los Angeles

Registration Number: NCT00002465

Locations: 🇺🇸
St. Vincent Medical Center - Los Angeles, Los Angeles, California, United States

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-29

Last Posted Date: 2013-07-24

Lead Sponsor: Yale University

Target Recruit Count: 40

Registration Number: NCT00002680

Locations: 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

Phase 2

Completed

Conditions: Fatigue
Cachexia
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-03-03

Last Posted Date: 2012-05-30

Lead Sponsor: Northwestern University

Registration Number: NCT00004912

Locations: 🇺🇸
University of Arkansas - Department of Geriatrics, North Little Rock, Arkansas, United States
🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸
Office of David Cella, Evanston, Illinois, United States

and more 3 locations

Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer

Phase 3

Completed

Conditions: Weight Changes
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Megestrol Acetate
Drug: Oxandrolone 20 mg

First Posted Date: 2003-10-07

Last Posted Date: 2021-09-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 155

Registration Number: NCT00070148

Locations: 🇺🇸
CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸
Alamance Cancer Center at Alamance Regional Medical Center, Burlington, North Carolina, United States
🇺🇸
Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States

and more 17 locations

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Phase 3

Terminated

Conditions: Endometrial Cancer

First Posted Date: 2003-09-09

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00016341

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

and more 47 locations

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

Phase 2

Completed

Conditions: Brain Tumor
Central Nervous System Tumors
Myelodysplastic Syndromes
Unspecified Childhood Solid Tumor, Protocol Specific
Myelodysplastic/Myeloproliferative Diseases
Cachexia
Leukemia
Lymphoma

Interventions: Drug: cyproheptadine hydrochloride
Drug: megestrol acetate

First Posted Date: 2003-08-07

Last Posted Date: 2014-02-03

Lead Sponsor: University of South Florida

Target Recruit Count: 70

Registration Number: NCT00066248

Locations: 🇺🇸
Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States

and more 40 locations

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

Phase 3

Completed

Conditions: Anorexia
Cachexia
Lung Cancer

First Posted Date: 2003-08-06

Last Posted Date: 2021-09-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT00031785

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy